S*Bio

About S*Bio

S*BIO Pte Ltd, a Singapore-based biotechnology firm, was established on May 26, 2000, as a joint venture between Chiron and the Singapore Economic Development Board Investments (EDBI). The company operates as a privately-held entity focused on the research and clinical development of novel targeted small molecule drugs for oncology. Its primary therapeutic areas revolve around kinase and histone deacetylase (HDAC) inhibitors.

The company's business model is centered on drug discovery and development, from preclinical research to clinical trials, with the goal of commercializing its drug candidates through partnerships and licensing agreements with larger pharmaceutical companies. For instance, S*BIO entered into a worldwide exclusive license with Tragara Pharmaceuticals to develop and commercialize SB1317 and had a collaboration with Onyx Pharmaceuticals for its JAK2 inhibitors. The firm's revenue stream is composed of upfront fees, milestone payments, and potential royalties from these agreements, as well as research fees for preclinical activities performed for partners.

S*BIO's drug pipeline includes several compounds that have progressed to clinical trials. One of its key programs is Pacritinib (also known as SB1518), a potent and orally-active JAK2 inhibitor. This drug candidate received orphan drug designation from the U.S. FDA and has been evaluated in Phase 2 and 3 clinical trials for myelofibrosis (MF), a chronic bone marrow condition. Another significant asset is SB939, a novel HDAC inhibitor. The company also developed SB1317 (or TG02), an oral multi-kinase inhibitor that entered Phase 1 trials for treating advanced hematologic malignancies. S*BIO has established a robust R&D infrastructure and maintains strong connections with a network of medical oncologists, particularly in the Asia Pacific region.